価格表

在庫・価格 : 2025年04月26日 18時06分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Human Phospho-EGF R DuoSet IC, 2 Plate
データシート※最新のデータシートでない場合があります
DYC1095B-2 RSDアールアンドディー システムズ
R&D Systems, Inc.
1 kit ¥83,000
(未発注)
追加

在庫・価格 : 2025年04月26日 18時06分 現在

Human Phospho-EGF R DuoSet IC, 2 Plate

  • 商品コード:DYC1095B-2
  • メーカー:RSD
  • 包装:1kit
  • 価格: ¥83,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Ramirez L et al. Stand-Sit Microchip for High-Throughput, Multiplexed Analysis of Single Cancer Cells. Sci Rep 2016 Sep;6:32505
Ramirez L et al
2016/01/01
Application: High Throughput Chip Assay PubMed
2 Floc'h N et al. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol. Cancer Ther. 2018 May;17(5):885-896
Floc'h N et al
2018/01/01
Species: Human PubMed
3 Liu M et al. EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 2007 Nov;37(5):578-88
Liu M et al
2007/01/01
Species: Human PubMed
4 Hickinson DM et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin. Cancer Res. 2010 Feb;16(4):1159-69
Hickinson DM et al
2010/01/01
Species: Human PubMed
5 O'Brien NA et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol. Cancer Ther. 2010 Jun;9(6):1489-502
O'Brien NA et al
2010/01/01
Species: Human PubMed
6 Kim S et al. CCL20/CCR6 feedback exaggerates epidermal growth factor receptor-dependent MUC5AC mucin production in human airway epithelial (NCI-H292) cells. J. Immunol. 2011 Mar;186(6):3392-400
Kim S et al
2011/01/01
PubMed
7 Su M et al. Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway. Drug Des Devel Ther 2017;11:3333-3341
Su M et al
2017/01/01
PubMed
8 Giorgio C et al. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PLoS ONE 2011;6(3):e18128
Giorgio C et al
2011/01/01
PubMed
9 Jedlinski A et al. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc. J. Oral Pathol. Med. 2017 Oct;46(9):717-724
Jedlinski A et al
2017/01/01
PubMed
10 Brave SR et al. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int. J. Oncol. 2011 Jul;39(1):271-8
Brave SR et al
2011/01/01
PubMed
11 Shankaran H et al. Quantifying the effects of co-expressing EGFR and HER2 on HER activation and trafficking. Biochem. Biophys. Res. Commun. 2008 Jun;371(2):220-4
Shankaran H et al
2008/01/01
PubMed
12 Kim S et al. Fibrinogen binding to ICAM-1 promotes EGFR-dependent mucin production in human airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2009 Jul;297(1):L174-83
Kim S et al
2009/01/01
PubMed
13 Sakai K et al. In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. Biochem. J. 2006 Aug;397(3):537-43
Sakai K et al
2006/01/01
PubMed
14 Ekerljung L et al. The HER2-binding affibody molecule (Z(HER2∶342))₂ increases radiosensitivity in SKBR-3 cells. PLoS ONE 2012;7(11):e49579
Ekerljung L et al
2012/01/01
PubMed
  • No.: 1
  • 文献情報:
    Ramirez L et al. Stand-Sit Microchip for High-Throughput, Multiplexed Analysis of Single Cancer Cells. Sci Rep 2016 Sep;6:32505
    Ramirez L et al
    2016/01/01
  • 備考:
    Application: High Throughput Chip Assay
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Floc'h N et al. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol. Cancer Ther. 2018 May;17(5):885-896
    Floc'h N et al
    2018/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Liu M et al. EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 2007 Nov;37(5):578-88
    Liu M et al
    2007/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Hickinson DM et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin. Cancer Res. 2010 Feb;16(4):1159-69
    Hickinson DM et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    O'Brien NA et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol. Cancer Ther. 2010 Jun;9(6):1489-502
    O'Brien NA et al
    2010/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Kim S et al. CCL20/CCR6 feedback exaggerates epidermal growth factor receptor-dependent MUC5AC mucin production in human airway epithelial (NCI-H292) cells. J. Immunol. 2011 Mar;186(6):3392-400
    Kim S et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Su M et al. Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway. Drug Des Devel Ther 2017;11:3333-3341
    Su M et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Giorgio C et al. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PLoS ONE 2011;6(3):e18128
    Giorgio C et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Jedlinski A et al. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc. J. Oral Pathol. Med. 2017 Oct;46(9):717-724
    Jedlinski A et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Brave SR et al. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int. J. Oncol. 2011 Jul;39(1):271-8
    Brave SR et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Shankaran H et al. Quantifying the effects of co-expressing EGFR and HER2 on HER activation and trafficking. Biochem. Biophys. Res. Commun. 2008 Jun;371(2):220-4
    Shankaran H et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Kim S et al. Fibrinogen binding to ICAM-1 promotes EGFR-dependent mucin production in human airway epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2009 Jul;297(1):L174-83
    Kim S et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Sakai K et al. In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. Biochem. J. 2006 Aug;397(3):537-43
    Sakai K et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Ekerljung L et al. The HER2-binding affibody molecule (Z(HER2∶342))₂ increases radiosensitivity in SKBR-3 cells. PLoS ONE 2012;7(11):e49579
    Ekerljung L et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed